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Abstract 
Objectives To evaluate the effect of pharmaceutical care (PC) on glycemic control in 
patients with type 2 diabetes mellitus. 
Methods A systematic search of literature was conducted to identify randomized 
controlled trials (RCTs) in patients with type 2 diabetes mellitus. RCTs published in 
English between January 2011 and November 2015 were identified using nine electronic 
databases: MEDLINE, International Pharmaceutical Abstracts (IPA), EMBASE, Scopus, 
Science Direct, Cochrane Library, Web of Science, Springer Link, and Google Scholar. 
Studies were included if they outlined a pharmaceutical care intervention conducted by 
pharmacists alone or in collaboration with other health care professional(s). The studies 
were identified and data was extracted independently by two reviewers. The meta-analysis 
was conducted by using RevMan version 5.3. A random-effects model was used to 
calculate the standard mean difference (SMD) with a 95% confidence interval in 
glycosylated hemoglobin (HbA1C) levels. 
Key findings Thirteen RCTs outlining PC interventions in type 2 diabetes mellitus 
patients (n=1828) were included. The interventions included care plan development, 
medication reviews, patient education and counselling of patients with follow-up. All 
RCTs reported statistically significant reductions in HbA1c in the intervention group 
(SMD = -0.97; 95% CI -1.21 to -0.73; p=0.00001) as compared to the control group. 
Significant heterogeneity in SMD (χ2= 68.96) was observed. 
Conclusions The findings suggest that PC interventions are effective (at least in short-
term follow-up in hospital setting) in reducing HbA1c levels in patients with type 2 
diabetes mellitus. Pharmacists, working alone or in collaboration with other health 
professionals have significant impact on improving the health status of patients with type 
2 diabetes mellitus. 
Keywords Glycemic control, meta-analysis, pharmaceutical care, randomized 
controlled trial  
  
Introduction 
Diabetes mellitus is a major public health concern. It was identified by world leaders in the 
2011 Political Declaration on the Prevention and Control of Non-communicable diseases 
as the one of the four major priority health conditions. It is a long-term condition associated 
with an higher incidence of morbidity and mortality; it has been reported that patients with 
diabetes mellitus have an 11 times greater morbidity than the non-diabetic population.[1] In 
addition, the prevalence of the condition is increasing worldwide. In 2010 global estimates 
reported the proportion of people with diabetes mellitus between the ages 20 to 79 years 
was 6.4%,[2] and in a World Health Organisation report on diabetes, it has been estimated 
that the number of patients with diabetes mellitus has doubled between 1980 and 2014.  
Diabetes can be controlled by modification of lifestyle and/or through adherence to 
antidiabetic medicine regimens. It has been well established that poor glycemic control 
leads to hospitalization, long-term complications, disease progression, premature disability 
and greater mortality.[3,4] A study conducted by Statton et al. found that for every 1% 
decrease in glycosylated hemoglobin (HbA1C) there was a 37% reduction in the risk of 
microvascular complications, 14% for myocardial infarction and 21% in diabetes related 
risk of death.[5] 
The role of the pharmacist has shifted over-time, from product-oriented practice, to a role 
that has a strong involvement in patient-centred care. The provision of pharmaceutical care 
(PC) has been one means by which this is being achieved. PC is the responsible provision 
of drug therapy to patients in-order to achieve defined outcomes and to improve patient 
quality of life.[6] Clinical pharmacists in collaboration with patients and other health 
professionals design, implement and monitor pharmaceutical care plans which are intended 
to identify and resolve actual drug-related problems (DRP) as well as preventing potential 
DRPs.[7] 
Studies have reported significant positive effects associated with PC as it relates to the 
control of HbA1C in type 2 diabetes patients.
[8,9] There have been published systematic 
reviews and meta-analyses on patient adherence to anti-diabetic medications (10, 11). 
Meta-analyses have also been conducted on randomized controlled trials (RCTs) published 
up until 2010,[12,13] and another included RCTs through to 2011,[14] albeit the database 
search was limited.  
  
The present meta-analysis was conducted to investigate an up-to-date evaluation of the 
effectiveness of PC on glycemic control. The objective was to report the main components 
of PC interventions and their impact on patient health outcomes in addition to providing 
an evaluation of the effect of PC on glycemic control of type 2 diabetes patients. 
  
  
Methods 
Search strategy 
A systematic search of literature was conducted to identify RCTs published in English 
between January 2011 and November 2015 by using the following electronic databases: 
MEDLINE (Ovid SP), International Pharmaceutical Abstracts (IPA), EMBASE, Scopus, 
Science Direct, Cochrane Library, Web of Science, Springer Link, and Google Scholar. 
Two authors (RK and ZUB) searched following keywords ‘pharmaceutical care’ or 
‘medicine management’ or ‘medicine therapy assessment’ or ‘pharmacy services’ or 
‘patient centered care’ or ‘pharmacist’ or ‘community pharmacist’ or ‘hospital pharmacist’ 
or ‘diabetes’ or ‘diabetes mellitus’. The search was restricted to randomized controlled trial 
only.  
Inclusion/exclusion process 
Two of the authors (RK and ZB) reviewed the titles and abstracts of all selected articles for 
relevance. In case of any doubt regarding inclusion each full text article was reviewed for 
relevance. Non-randomized and secondary studies including literature reviews, systematic 
reviews and meta-analyses were excluded.  
Data extraction and quality assessment   
The following characteristics were documented for each study included in this review: 
authors, country, sample size, study design, study population, follow up period, study 
setting, study outline (intervention provided) outcome measure and the effect of the 
intervention. Two reviewers (RK & ZB) extracted the data and rated the studies for quality 
and outcome measures. The quality of studies were evaluated according to a hierarchy of 
study designs reported by the Scottish Intercollegiate Guidelines Network (SIGN).[15] 
Quantitative Data Synthesis 
In this meta-analysis, the authors included all those studies that reported appropriate data. 
The majority of studies only reported the means and standard deviations (SD) of HbA1c at 
baseline and at the final point, for both intervention and control groups without calculation 
of means and SD changes in HbA1c from baseline to the final recording. For these studies, 
  
means and SD changes from baseline to final point were calculated using the methods 
described in the Cochrane Handbook for Systematic Reviews of Interventions 5.0.2.[16] In 
this manner, the change in mean of HbA1c in each group was calculated by subtraction of 
the final mean value from the baseline mean value. The missing SD change in HbA1c level 
was substituted by an imputed value. For example, the SD change in HbA1c in intervention 
group was calculated using the following formula: 
 
SD(C) = √SD (B)2+ SD(E)2 – (2 × R × SD(B) × SD(E) 
 
Where, SD(C) was the SD change of HbA1c level in the intervention 
group, SD(B) was the SD of baseline HbA1c level in the intervention 
group, SD(E) was the final SD of HbA1C level in the intervention group 
and R was the correlation coefficient.  
 
The value of correlation coefficient (R) was calculated from one study reporting the 
complete data and hence was substituted into the calculation of the overall change of SD. 
Assuming that one study (RCTx), included in the present meta-analysis reported the values 
of means and SD of HbA1C level for change and for baseline and final point and then the 
formula could be presented as:  
 
R= SDx (B)
2+ SDx(E)
2 –SDx(C)2 
2 × SDx (B) × SDx(E) 
 
Where, SDx(B) was the baseline SD ofHbA1C level of the intervention 
group in RCTx, SDx(E) was the final SD of HbA1C level of the 
intervention group in RCTx, and SDx(C) was the SD change of HbA1C 
level of the intervention group in RCTx. The SD change of HbA1C level 
in control groups was also be calculated by using the above formulas. 
 
In the present meta-analysis, the outcome of interest was the mean reduction in HbA1c 
level of the intervention and control groups over the follow-up period of the study. For the 
meta-analysis of continuous data, standard mean difference (SMD) the estimated 
  
confidence intervals (CIs) for SMD were 95%. The Chi square (χ2) test was used to evaluate 
the heterogeneity between the included studies. A p value ≤ 0.1 was considered as 
statistically significant. In the presence of heterogeneity (p value ≤0.1), the outcomes were 
combined by using a random-effect model whereas in the absence of heterogeneity (p value 
≥0.1), outcomes were combined by using the fixed-effect model. Visual inspection of 
funnel plot of SMD against standard error (SE) was used to identify the publication bias. 
Asymmetry of funnel plot was tested by Egger’s test (p value ≤0.05 was statistical 
significant). Statistical analysis was performed by using Review Manager (version 5.3). 
  
  
Results 
Selection and characteristics of studies   
The literature search identified 1989 titles/abstracts and those containing key terms were 
selected (n=291). A total of 205 studies were found after removing duplicates. Thirteen 
randomized controlled trials (RCTs) fulfilled the inclusion and exclusion criteria of study 
and were included in this meta-analysis.  
 
The studies were conducted in USA,[17] UK,[18] Belgium,[19] Brazil,[20] Jordan,[21] 
Taiwan,[22] Iraq,[23] Iran,[24] India,[25] China,[26,27] and Malaysia.[28,29] Figure 1 depicts the 
study selection conducted according to the PRISMA (Preferred reporting items for 
systematic reviews and meta-analyses) Statement. 
 
From the thirteen trials, eleven RCTs were conducted at a single centre (hospitals or clinic) 
while two were multicentre studies (community pharmacies). Seven RCTs included 
follow-up period of ≤ 6 months, the remainder being greater than 6 months. The total 
patient sample across all the studies was 1828 patients. All 13 RCTs included type 2 
diabetes mellitus patients. Eleven of the 13 RCTs reported the age of patients and only 
included adults. The basic characteristics of the studies included are summarized in Table 
1. 
Methodological quality of included studies  
The methodological quality of the included RCTs was variable. Allocation concealment 
from the patients was not feasible; therefore, RCTs have not properly described how they 
address the allocation concealment. Due to the nature of pharmaceutical care interventions, 
the majority of the RCTs were not completely blinded. Two RCTs were assigned 1++, six 
RCTs as 1+ and five RCTs were assigned 1-. These scores are listed in Table 1. 
Types of interventions included 
The basic components of the interventions are summarized in Table 2. Eleven studies 
included interventions provided by clinical pharmacists in the hospital setting and two 
studies involved service provision via community pharmacists. Four RCTs described the 
training pharmacists received including an 8-hour diabetes training program, ambulatory 
care training, training session on pathophysiology of T2DM and pharmacological and non-
  
pharmacological management and certified diabetes education. The basic components of 
interventions included: care plan development, medication review, patient education and 
counselling regarding diabetes, its complications, medications, life-style modification, 
exercise and self-monitoring. In some studies, patients received verbal as well as written 
information. Almost all RCTs included patient- pharmacist’s face-to-face interviews 
however, some studies also included follow-up telephone calls along with patient visits to 
the study site. 
Impact of pharmacists’ interventions on change in HbA1c level 
Ten RCTs reported change in HbA1c level as the primary clinical outcome and in three 
RCTs it was the secondary clinical outcome. Two RCTs reported mean and SD changes of 
HbA1c level from baseline to final point for both groups. Eleven RCTs included the means 
(and SD) of HbA1c levels for both groups at baseline and final point. For these studies the 
mean (and SD) changes of HbA1c levels were calculated for both groups by using an 
imputed value. Differences in changes of HbA1c between intervention and control groups 
are summarized for each study in Table 3. 
All RCTs have shown statistically significant reductions in HbA1c level. This showed that 
pharmacists’ interventions led to an improved glycemic control as compared to control 
group. There was significant heterogeneity of SMD (χ2= 68.96: df=12; p=0.00001). Thus, 
the random effect (RE) model was used to combine the outcomes. The pooled estimate of 
13 trials presented a statistically significant reduction in HbA1c for intervention group 
patients in comparison to control group patients. The SMD and 95% CIs for 13 RCTs 
analysed are presented as a forest plot in Figure 2. The present study reported a statistically 
significant difference in pooled effect size that favoured the pharmaceutical care group 
over the control group (SMD = -0.97; 95% CI -1.21 to -0.73; z = 7.87; p=0.00001).  
Potential publication bias 
Publication bias (also known as reporting bias) was evaluated by creating a Begg-
Mazumdar’s funnel plot (Figure 3). The results did not show any publication bias in the 
studies. 
  
  
Discussion 
Glycemic control represented by HbA1c, is an important test for the measurement of 
effective blood glucose control in diabetic patients over time. The aim of the present meta-
analysis was to collect and quantitatively analyze HbA1c data from RCTs that 
implemented a pharmaceutical care intervention that involved a pharmacist. The results of 
this analysis would therefore provide evidence as to whether pharmaceutical care 
interventions were effective in reducing HbA1c levels in patients with diabetes type 2 and 
what these interventions were. The findings of this meta-analysis report a statistically 
significant reduction in the HbA1c level i.e. ≥0.50% in the pharmaceutical care 
intervention group as compared to controls. These results are consistent with the findings 
of an earlier meta-analysis demonstrating significant improvements in diabetic patients 
receiving pharmaceutical care.[12,30] It would appear that the effects of the pharmaceutical 
care model have been sustainable over time. 
The components of pharmaceutical care which were most commonly implemented 
included: care plan development, medication review, patient education (via verbal and 
written information) and counselling regarding diabetes, its complications, medications, 
life-style modification, exercise and self-monitoring. RCTs with patient education relating 
to self-monitoring and self-management of diabetes reported statistically significant 
improvements in glycosylated hemoglobin levels. These findings provided the evidence 
for the effective role of pharmacists in patient education and counselling. Our findings are 
supported by a previous meta-analysis (that included studies published prior to 1999), that 
reported effective patient education led to statistically significant improvement in glycemic 
control.[31]  
Four RCTs included interventions conducted by well-trained pharmacists reporting 
statistically significant decreases in HbA1c levels in the intervention group compared with 
the control group. These findings highlight the importance of well-trained pharmacists for 
successful implementation of PC and for improving the patient outcomes. The present 
study findings are in line with a previous systematic review showing the improved 
outcomes resulted from the interventions conducted by well-trained interventionists 
(pharmacists).[32] 
  
The emergence of clinical pharmacy services is at early stages of development in some 
developing countries. In the present meta-analysis, except for three RCTs (US, UK, 
Belgium) all the others were conducted in developing countries (Brazil, China, Jordan, 
India, Iran, Iraq, Malaysia and Taiwan). Type 2 diabetes has become a major health 
problem in developing countries; therefore, strategies are required for treatment as well as 
prevention of this condition. The findings from a recent systematic review and meta-
analysis provided the evidence for the effectiveness of different strategies in type 2 diabetes 
mellitus prevention.[33]  
The present systematic review showed that RCTs with follow-up of greater than 6 months 
report more significant mean reductions in HbA1c levels than RCTs with shorter follow-
up. This suggests that better control is afforded through sustained PC interventions. The 
present study supports the previous meta-analysis in reporting a high mean reduction in 
glycosylated hemoglobin level resulting from longer follow-up.[13]  
Implications for practice 
The main aim of this study was to evaluate the effect of pharmaceutical care on glycemic 
control in patients with type 2 diabetes mellitus. We have done so by systematically 
searching and reporting on the outcome of pharmaceutical care in the management of type 
2 diabetes, with special attention to the effect of pharmacists’ interventions. Our findings 
suggest that globally, there is great variability in the use of pharmaceutical care for 
achieving clinical outcomes (e.g. glycemic control). Published RCTs have clearly 
demonstrated that pharmaceutical care interventions are effective in glycemic control in 
type 2 diabetes mellitus patients. The literature also shows that pharmacists have specific 
set of skills, strategies, and practices related to medicines use and this sets apart the work 
of the pharmacist from other members of the healthcare team. The data also suggest the 
description of the interventions regarding how to develop and support the patient-centred 
activities in the management of type 2 diabetes. 
Limitations 
The present meta-analysis has limitations based on the reporting bias in some of the RCTs 
that may be due to the reporting of the desired outcome (reduction in HbA1c) as a 
  
secondary outcome measure. Furthermore, there is heterogeneity in the studies including; 
smaller study sample size, shorter follow-up time period and study setting.  
This study quantitatively analyses only RCTs and excludes all other interventional studies 
including; non-RCTs, cohort and pre-post studies to minimize the selection bias of patients. 
Additionally, the present study includes only patients diagnosed with type 2 diabetes 
mellitus to minimize the heterogeneity of the patient population. The results cannot be 
generalized to community pharmacies as most the clinical trials included were performed 
in hospitals or clinics. Future research is needed with pharmaceutical care conducted by 
well-trained pharmacists with longer term follow-up. 
Conclusion 
Quantitative analysis of the collective literature suggests that pharmaceutical care 
interventions are effective (at least in short-term follow-up in hospital setting) in reducing 
HbA1c levels in type 2 diabetes mellitus patients. Pharmacists working alone or in 
collaboration with other health professionals have a significant impact on improving the 
health status of patients with type 2 diabetes mellitus. 
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Table 1. Basic characteristics of included studies (n=13) 
Reference  Country Sample 
size 
(completed 
follow-up) 
Study site Study 
design 
Randomization 
method 
Study 
population 
Quality 
grade 
Wishah et al.  
(2015) 
Jordan 106 
patients 
(IG= 52 
CG=54) 
Diabetes 
clinic 
Jordan 
University 
Hospital 
Randomized 
controlled 
clinical trial 
Coin-toss 
method 
Aged ≥18 
years, 
diagnosed 
with type 2 
diabetes 
(T2DM), 
HbA1C 
≥6.5% for 
initial 
diagnosis and 
>7% for 
uncontrolled 
diabetes 
1+ 
Chen et al. 
(2015) 
Taiwan 100 
patients 
(IG=50 
CG=50) 
Nantou 
Hospital 
Randomized 
controlled 
trial 
Random 
numbers 
generated by 
SAS 9.2 
Aged ≥65 
years, 
ambulatory 
patients with 
T2DM, with 
HbA1C 
≥9.0% 
1+ 
Xin et al. 
(2015) 
China 227 
patients      
(IG=114 
CG=113) 
Tongde 
Hospital 
Prospective 
Randomized 
controlled 
study 
NR Aged ≥18 
years, 
diagnosed 
with T2DM, 
patients had 
no evidence 
of filled 
prescription 
in insulin 
therapeutic 
during 
previous 18 
months  
1+ 
Butt et al. 
(2015) 
Malaysia 66 patients 
(IG=33 
CG=33) 
University 
Medical 
center 
Randomized 
controlled 
study 
Envelop 
picking 
Diagnosed 
with poorly 
controlled 
T2DM with 
HbA1C ≥8% 
1++ 
Cani et al. 
(2015) 
 
Brazil 70 patients  
(IG=34 
CG=36) 
Diabetes 
out-patient 
clinic of 
hospital 
Randomized 
controlled 
trial 
Simple 
randomization  
Aged ≥45 
years, 
Diagnosed 
with T2DM 
and on insulin 
1- 
  
prescription, 
HbA1C >8% 
Chung et al. 
(2014) 
Malaysia 241 
patients 
(IG=120 
CG=121) 
Teaching 
hospital 
Prospective 
Randomized 
controlled 
trial 
NR Aged 21-75 
years 
T2DM, 
taking at-least 
one anti-
diabetic 
medication, 
HbA1C ≥8% 
1- 
Mahwi et al. 
(2013) 
Iraq 123 
patients  
(IG=62 
CG=61) 
Diabetes 
center 
Prospective 
Randomized 
controlled 
trial 
Simple 
randomization 
technique 
Aged 30-80 
years, T2DM 
patients 
1- 
Ali et al.  
(2012) 
England 46 patients 
(IG=23 
CG=23) 
2 
community 
pharmacies 
Randomized 
controlled 
study 
Computer 
generated 
randomized list  
Aged >18 
years, 
T2DM and 
oral 
medication, 
HbA1C ≥7% 
1+ 
Chan et al. 
(2012) 
China 105 
patients  
(IG=51 
CG=54) 
Diabetes 
clinic 
Randomized 
controlled 
study 
Computer 
generated and 
sealed envelope 
(pharmacists 
were blind) 
Aged ≥ 18 
years, T2DM, 
with at least 5 
drugs (1 
hypoglycemic 
drug) and 
HbA1C ≥8% 
1++ 
Jacobs et al. 
(2012) 
USA 164 
patients  
(IG=72 
CG=92) 
Lahey 
clinic in 
Burlington 
Randomized 
controlled 
practice 
study 
Computer 
randomized 
sequence of 
ones and zeros 
Aged > 18 
years, T2DM, 
HbA1C >8% 
1+ 
Farsaei et al. 
(2011) 
Iran 172 
patients 
(IG=86 
CG=86) 
Isfahan 
Endocrine 
and 
Metabolism 
Research 
Center 
Randomized 
controlled 
clinical trial 
NR T2DM 
patients, 
HbA1C >7%, 
with stable 
therapeutic 
condition 
1- 
Mehuys et al. 
(2011) 
Belgium 288 
patients 
(IG=153 
CG=135) 
66 
community 
pharmacies 
Randomized 
controlled 
parallel 
group trial 
Randomization 
was done at 
pharmacy level 
by random 
numbers table 
generated by 
using SPSS 
14.0 software 
Aged 45-75 
years, T2DM 
patients, on 
oral 
hypoglycemic 
medication 
1+ 
Sriram et al. 
(2011) 
India 120 
patients 
(IG=60 
CG=60) 
Tertiary 
care 
teaching 
hospital 
Prospective 
randomized 
trial 
Random 
number table 
Aged >18 
years, 
T2DM 
patients 
1- 
 
 
 
 
 
  
 
 
 
 
 
 
Table 2. Basic components of interventions in RCTs (n=13) 
Refere
nce  
Follow 
up period  
Interventions provided Interventioni
st (team 
members) 
Training of 
interventioni
st 
Usual care HbA1C 
reported 
outcome 
measure 
Wisha
h et al.  
(2015) 
6 months Individual patient care plan was 
developed and discussed with 
physician. Pharmacist provided 
patient education and counselling 
about disease and medication. 
Printed leaflets were also given 
to patients.  
Clinical 
pharmacist, 
physician 
N/A Usual care 
provided by 
medical and 
nursing staff 
Primary 
outcome 
Chen 
et al. 
(2015) 
6 months Pharmaceutical care comprised 
of assessment of adherence to pill 
box use and insulin injection 
technique. Diabetes-related care 
was provided including patient 
education and recommendation 
to physician and referral to 
diabetes care team 
Clinical 
pharmacist  
Pharmacist 
was a 
certified 
diabetes 
educator 
Usual care Primary 
outcome 
measured 
every 3 or 6 
months  
Xin et 
al. 
(2015) 
12 months Pharmaceutical care program 
was developed for individual 
patient. Intervention consist of 
individualized education, 
educative group activities and 
telephone counselling 
Clinical 
pharmacist 
NR Usual care 
with 
appointments 
with physician 
once every 
month 
Secondary 
outcome 
Butt et 
al. 
(2015) 
6 months Patients received usual as well as 
pharmacist care. Patients 
received counselling about 
diabetes, complications, 
medication, adherence, life-style 
modification and self-
monitoring.  
Clinical 
pharmacist 
NR Patient-
physician 
meeting 
ranging every 
4 to 9 months. 
Patients with 
poor glycemic 
control were 
referred to 
nurse diabetes 
educator 
Primary 
outcome 
Cani et 
al. 
(2015) 
6 months Individualized pharmacotherapy 
plan was developed. Patients 
were educated. Pill organizers 
were given. Written information 
on acute and chronic 
complications and importance of 
life style changes and regular 
foot inspection etc. 
Clinical 
pharmacist 
NR Standard care. 
They did not 
receive advice 
from clinical 
pharmacist but 
were allowed 
to request 
information 
anytime  
Primary 
outcome 
  
Chung 
et al. 
(2014) 
12 months Pharmaceutical care. Pharmacist 
reviewed the medications and 
tried to resolve any DRPs. 
Patients received education about 
disease as well as medication. 
Received monthly follow-up 
telephone calls. 
Clinical 
pharmacist 
NR Standard 
pharmacy 
services 
Primary 
outcome 
Mahwi 
et al. 
(2013) 
4 months  Pharmaceutical care. Patients 
were followed for 3 visits with 
continuous weekly telephone 
calls 
Clinical 
pharmacist 
NR Standard 
medical care 
Primary 
outcome 
Ali et 
al.  
(2012) 
12 months Pharmacists carried out 
medication review, life style 
modification counselling. 
Patients were seen by 
pharmacists every month for 12 
months  
Community 
pharmacist 
Pharmacists 
undertook an 
8-hours 
training 
program 
Usual care 
received from 
physicians, 
practice nurse 
and 
community 
pharmacy 
Primary 
outcome 
Chan 
et al. 
(2012) 
9 months Patients were interviewed by 
pharmacist before each 
physician visit. Complete 
medication history was recorded 
and importance of medication 
adherence was reinforced 
Clinical 
pharmacist 
NR Patients 
received same 
medical care 
without 
pharmacist 
Secondary 
outcome 
Jacobs 
et al. 
(2012) 
12 months Comprehensive medication 
review, education on diabetes 
and therapies, facilitating self-
monitoring of blood glucose and 
dietary guidelines and exercise  
5 Clinical 
pharmacists 
1 pharmacist 
was trained in 
ambulatory 
care and 
experience in 
chronic 
disease 
patients. 
Other 4 
pharmacists 
have 10 
years’ 
experience in 
ambulatory 
care practice 
Usual care 
provided by 
physicians  
Primary 
outcome 
Farsaei 
et al. 
(2011)  
3 months Patients participated in two 
educational sessions. First 
session was about classification 
of anti-hyperglycemic agents and 
the second was education 
regarding adherence and self-
management. Patients were 
followed by weekly telephone 
calls 
Clinical 
pharmacist 
NR General 
education 
provided by 
nursing staff 
Primary 
outcome 
Mehuy
s et al. 
(2011) 
6 months Education about T2DM, 
hypoglycemic agents, 
medication adherence, healthy 
life-style, and reminders about 
eye and foot examination 
Community 
pharmacists 
Training 
session on 
pathophysiolo
gy of T2DM 
and 
pharmacologi
cal and non-
pharmacologi
cal 
management  
Usual care Primary 
outcome 
  
Sriram 
et al. 
(2011) 
8 months Pharmaceutical care including 
medication counseling, 
instructions on diet regulation, 
exercise and life-style 
modification. Written 
information was also provided 
Clinical 
pharmacist 
NR Usual care No clear 
description 
as primary 
or secondary 
But I think it 
is sec 
 
 
 
 
 
Table 3. Influence of pharmacists’ interventions on HbA1c (%) 
References Intervention group Control group 
Average differences 
in A1c values (Mean 
±SD) 
Patient 
numbers 
Average 
differences in A1c 
values (Mean ±SD) 
Patient 
numbers 
Wishah et al. (2015) -1.7±1.24 52 -0.3±1.12 54 
Chen et al. (2015) -0.83±1.31 50 0.43±1.3 50 
Xin et al. (2015) -2.36±2.14 114 -0.77±1.71 113 
Butt et al. (2015) -1.19±1.35 33 -0.38±1.31 33 
Cani et al. (2015) -0.57±1.26 34 -0.08±1.34 36 
Chung et al. (2014) -1.4±1.1 120 -0.2±1.42 121 
Mahwi et al. (2013) -2.33±1.63 62 -0.47±2.17 61 
Ali et al. (2012) -1.6±1.34 23 -0.6±0.75 23 
Chan et al. (2012) -1.57±1.50 51 -0.40±1.19 54 
Jacobs et al. (2012) -1.8±1.03 72 -0.8±1.24 92 
Farsaei et al. (2011) -1.8±1.4 86 0.1 ±1 86 
Mehuys et al. (2011) -0.6 ±1.30 153 -0.1±0.96 135 
Sriram et al. (2011) -1.71±0.5 60 -0.72±0.39 60 
 
 
 
 
 
 
  
 
 
 
  
 
Figure 2. Forest plot of HbA1c change between intervention group and control group (effect size)
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Total (95% CI)
Heterogeneity: Tau² = 0.16; Chi² = 68.96, df = 12 (P < 0.00001); I² = 83%
Test for overall effect: Z = 7.87 (P < 0.00001)
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-0.1
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Figure 3. Funnel plot of standard error against standard mean difference (SMD) 
 
 
 
 
 
 
 
 
 
